Decision-making and challenges within the evolving treatment algorithm in spinal muscular atrophy: a clinical perspective

References

• Lefebvre S, Bürglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155–165. DOI:10.1016/0092-8674(95)90460-3
   PubMed Web of Science ®Google Scholar
• Burghes AH, Beattie CE. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? Nat Rev Neurosci. 2009;10(8):597–609.
   PubMed Web of Science ®Google Scholar
• Monani UR, Lorson CL, Parsons DW, et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet. 1999;8(7):1177–1183. DOI:10.1093/hmg/8.7.1177
   PubMed Web of Science ®Google Scholar
• Feldkötter M, Schwarzer V, Wirth R, et al. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet. 2002;70(2):358–368.
   PubMed Web of Science ®Google Scholar
• Wirth B. Spinal muscular atrophy: in the challenge lies a solution. Trends Neurosci. 2021;44(4):306–322.
   PubMed Web of Science ®Google Scholar
• Kirschner J, Butoianu N, Goemans N, et al. European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy. Eur J Paediatr Neurol. 2020;28:38–43.
   PubMed Web of Science ®Google Scholar
• Glascock J, Sampson J, Connolly AM, et al. Revised recommendations for the treatment of infants diagnosed with spinal muscular atrophy via newborn screening who have 4 copies of SMN2. J Neuromuscul Dis. 2020;7(2):97–100. DOI:10.3233/JND-190468
   PubMedGoogle Scholar
• Kichula EA, Proud CM, Farrar MA, et al. Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy. Muscle Nerve. 2021;64(4):413–427. DOI:10.1002/mus.27363
   PubMed Web of Science ®Google Scholar
• Ribero VA, Daigl M, Martí Y, et al. How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison. J Comp Eff Res. 2022;11(5):347–370. DOI:10.2217/cer-2021-0216
   PubMed Web of Science ®Google Scholar
• Bischof M, Lorenzi M, Lee J, et al. Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1. Curr Med Res Opin. 2021;37(10):1719–1730.
   PubMed Web of Science ®Google Scholar
• Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723–1732. DOI:10.1056/NEJMoa1702752
   PubMed Web of Science ®Google Scholar
• Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378(7):625–635. DOI:10.1056/NEJMoa1710504
   PubMed Web of Science ®Google Scholar
• Claudia A. Chiriboga, Basil T. Darras, Michelle A. Farrar, et al. Longer-term treatment with nusinersen: results in later-onset spinal muscular atrophy from the SHINE Study (1661). Neurol.; 2020; 94 (15 Supplement) 1661.
   Google Scholar
• Finkel RS, Ryan MM, Pascual Pascual SI, et al. Scientific rationale for a higher dose of nusinersen. Ann Clin Transl Neurol. 2022;9(6):819–829. DOI:10.1002/acn3.51562
   PubMed Web of Science ®Google Scholar
• De Vivo DC, Bertini E, Swoboda KJ, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study. Neuro Disord. 2019;29(11):842–856.
   PubMed Web of Science ®Google Scholar
• Michelson D, Ciafaloni E, Ashwal S, et al. Evidence in focus: nusinersen use in spinal muscular atrophy: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology. 2018;91(20):923–933. DOI:10.1212/WNL.0000000000006502
   PubMed Web of Science ®Google Scholar
• Pechmann A, Behrens M, Dörnbrack K SMArtCARE study group , et al. Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy. Brain: J. Neurol. 2023 146(2):668–677. DOI:10.1093/brain/awac252
   Web of Science ®Google Scholar
• Coratti G, Cutrona C, Pera MC, et al. Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis. Orphanet J Rare Dis. 2021;16(1):430. DOI:10.1186/s13023-021-02065-z
   PubMed Web of Science ®Google Scholar
• Osredkar D, Jílková M, Butenko T, et al. Children and young adults with spinal muscular atrophy treated with nusinersen. Eur J Paediatr Neurol. 2021;30:1–8.
   PubMed Web of Science ®Google Scholar
• Acsadi G, Crawford TO, Müller-Felber W, et al. Safety and efficacy of nusinersen in spinal muscular atrophy: the EMBRACE study. Muscle Nerve. 2021;63(5):668–677. DOI:10.1002/mus.27187
   PubMed Web of Science ®Google Scholar
• Aragon-Gawinska K, Daron A, Ulinici A, et al. Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen. Dev Med Child Neurol. 2020;62(3):310–314. DOI:10.1111/dmcn.14412
   PubMed Web of Science ®Google Scholar
• Pane M, Coratti G, Pera MC, et al. Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy. Ann Clin Transl Neurol. 2022;9(3):404–409. DOI:10.1002/acn3.51514
   PubMed Web of Science ®Google Scholar
• Panagiotou P, Kanaka-Gantenbein C, Kaditis AG. Changes in ventilatory support requirements of Spinal Muscular Atrophy (SMA) patients post gene-based Therapies. Children (Basel). 2022;9(8):1207.
   PubMed Web of Science ®Google Scholar
• Weststrate H, Stimpson G, Thomas L, et al. Evolution of bulbar function in spinal muscular atrophy type 1 treated with nusinersen. Dev Med Child Neurol. 2022;64(7):907–914. DOI:10.1111/dmcn.15171
   PubMed Web of Science ®Google Scholar
• Duong T, Wolford C, McDermott MP, et al. Nusinersen treatment in adults with spinal muscular atrophy. Neurol Clin Pract. 2021;11(3):e317–e27. DOI:10.1212/CPJ.0000000000001033
   PubMedGoogle Scholar
• LoMauro A, Romei M, Priori R, et al. Alterations of thoraco-abdominal volumes and asynchronies in patients with spinal muscle atrophy type III. Respir Physiol Neurobiol. 2014;197:1–8.
   PubMed Web of Science ®Google Scholar
• Chacko A, Marshall J, Taylor O, et al. Dysphagia and lung disease in children with spinal muscular atrophy treated with disease modifying agents. Neurology. 2023;100(19):914–920.
   PubMed Web of Science ®Google Scholar
• Darras BT, Chiriboga CA, Iannaccone ST, et al. Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1/2 studies. Neurology. 2019;92(21):e2492–e2506. DOI:10.1212/WNL.0000000000007527
   PubMed Web of Science ®Google Scholar
• Montes J, Dunaway Young S, Mazzone ES, et al. Nusinersen improves walking distance and reduces fatigue in later-onset spinal muscular atrophy. Muscle Nerve. 2019;60(4):409–414. DOI:10.1002/mus.26633
   PubMed Web of Science ®Google Scholar
• Veerapandiyan A, Eichinger K, Guntrum D, et al. Nusinersen for older patients with spinal muscular atrophy: a real‐world clinical setting experience. Muscle Nerve. 2020;61(2):222–226. DOI:10.1002/mus.26769
   PubMed Web of Science ®Google Scholar
• Walter MC, Wenninger S, Thiele S, et al. Safety and treatment effects of nusinersen in longstanding adult 5q-SMA Type 3 - a prospective observational study. J Neuromuscul Dis. 2019;6(4):453–465. DOI:10.3233/JND-190416
   PubMedGoogle Scholar
• Hagenacker T, Hermann A, Kamm C, et al. Spinal Muscular Atrophy - expert recommendations for the use of nusinersen in adult patients. Fortschr Neurol Psychiatr. 2019;87(12):703–710. DOI:10.1055/a-0996-0994
   PubMed Web of Science ®Google Scholar
• Maggi L, Bello L, Bonanno S, et al. Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. J Neurol Neurosurg Psychiatry. 2020;91(11):1166–1174. DOI:10.1136/jnnp-2020-323822
   PubMed Web of Science ®Google Scholar
• Meyer T, Maier A, Uzelac Z, et al. Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersen. Eur J Neurol. 2021;28(8):2582–2595. DOI:10.1111/ene.14902
   PubMed Web of Science ®Google Scholar
• Darras BT, Farrar MA, Mercuri E, et al. An integrated safety analysis of infants and children with symptomatic Spinal Muscular Atrophy (SMA) treated with nusinersen in seven clinical trials. CNS Drugs. 2019;33(9):919–932. DOI:10.1007/s40263-019-00656-w
   PubMed Web of Science ®Google Scholar
• Ortiz CB, Kukreja KU, Lotze TE, et al. Ultrasound-guided cervical puncture for nusinersen administration in adolescents. Pediatr Radiol. 2019;49(1):136–140.
   PubMed Web of Science ®Google Scholar
• Weaver JJ, Natarajan N, Shaw DWW, et al. Transforaminal intrathecal delivery of nusinersen using cone-beam computed tomography for children with spinal muscular atrophy and extensive surgical instrumentation: early results of technical success and safety. Pediatr Radiol. 2018;48(3):392–397. DOI:10.1007/s00247-017-4031-6
   PubMed Web of Science ®Google Scholar
• Kizina K, Stolte B, Totzeck A, et al. Clinical Implication of dosimetry of computed tomography- and fluoroscopy-guided intrathecal therapy with nusinersen in adult patients with spinal muscular atrophy. Front Neurol. 2019;10:1166.
   PubMed Web of Science ®Google Scholar
• Iannaccone ST, Paul D, Castro D, et al. Delivery of nusinersen through an ommaya reservoir in spinal muscular atrophy. J Clin Neuromuscul Dis. 2021;22(3):129–134.
   PubMedGoogle Scholar
• Mendell J, Al-Zaidy S, Shell R, et al. AVXS-101 phase 1 gene therapy clinical trial in SMA type 1: end-of-study event free survival and achievement of developmental milestones. J Neuromuscular Disorders. 2017;27:S208.
   Google Scholar
• Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713–1722. DOI:10.1056/NEJMoa1706198
   PubMed Web of Science ®Google Scholar
• Lowes LP, Alfano LN, Arnold WD, et al. Impact of age and motor function in a phase 1/2a study of infants with SMA type 1 receiving single-dose gene replacement therapy. Pediatr Neurol. 2019;98:39–45.
   PubMed Web of Science ®Google Scholar
• Mendell JR, Al-Zaidy SA, Lehman KJ, et al. Five-year extension results of the phase 1 start trial of onasemnogene abeparvovec in spinal muscular atrophy. JAMA Neurol. 2021;78(7):834–841. DOI:10.1001/jamaneurol.2021.1272
   PubMed Web of Science ®Google Scholar
• Day JW, Finkel RS, Chiriboga CA, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(4):284–293. DOI:10.1016/S1474-4422(21)00001-6
   PubMed Web of Science ®Google Scholar
• Mercuri E, Muntoni F, Baranello G, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (Str1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(10):832–841. DOI:10.1016/S1474-4422(21)00251-9
   PubMed Web of Science ®Google Scholar
• Strauss KA, Farrar MA, Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. Nat Med. 2022;28(7):1390–1397. DOI:10.1038/s41591-022-01867-3
   PubMed Web of Science ®Google Scholar
• Strauss KA, Farrar MA, Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. Nat Med. 2022;28(7):1381–1389. DOI:10.1038/s41591-022-01866-4
   PubMed Web of Science ®Google Scholar
• D’Silva AM, Holland S, Kariyawasam D, et al. Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy. Ann Clin Transl Neurol. 2022;9(3):339–350. DOI:10.1002/acn3.51519
   PubMed Web of Science ®Google Scholar
• Chand D, Mohr F, McMillan H, et al. Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy. J Hepatol. 2021;74(3):560–566. DOI:10.1016/j.jhep.2020.11.001
   PubMed Web of Science ®Google Scholar
• Feldman AG, Parsons JA, Dutmer CM, et al. Subacute liver failure following gene replacement therapy for spinal muscular atrophy type 1. J Pediatr. 2020;225:252–8.e1.
   PubMed Web of Science ®Google Scholar
• Chand DH, Zaidman C, Arya K, et al. Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series. J Paediatr. 2021;231:265–268.
   PubMed Web of Science ®Google Scholar
• Novartis. Zolgensma acute liver failure update. 2022. https://www.novartis.com/news/zolgensma-acute-liver-failure-update.
   Google Scholar
• Darras BT, Masson R, Mazurkiewicz-Bełdzińska M, et al. Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls. N Engl J Med. 2021;385(5):427–435. DOI:10.1056/NEJMoa2102047
   PubMed Web of Science ®Google Scholar
• Mercuri E, Baranello G, Boespflug-Tanguy O, et al. Risdiplam in types 2 and 3 spinal muscular atrophy: a randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment. Eur J Neurol. 2022. DOI:10.1111/ene.15499.
   PubMed Web of Science ®Google Scholar
• Finkel RS, Farrar MA, Vlodavets D , et al., editors. Rainbowfish: preliminary efficacy and safety data in Risdiplam-treated infants with presymptomatic spinal muscular atrophy (SMA). Anaheim, California: Annual Spinal Muscular Atrophy Research and Clinical Care Meeting; 2022.
   Google Scholar
• Kwon JM, Arya K, Kuntz N, et al. An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy. Ann Clin Transl Neurol. 2022;9(6):810–818. DOI:10.1002/acn3.51560
   PubMed Web of Science ®Google Scholar
• Van Alstyne M, Tattoli I, Delestrée N, et al. Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit. Nat Neurosci. 2021;24(7):930–940. DOI:10.1038/s41593-021-00827-3
   PubMed Web of Science ®Google Scholar
• Matesanz SE, Battista V, Flickinger J, et al. Clinical experience with gene therapy in older patients with spinal muscular atrophy. Pediatr Neurol. 2021;118:1–5.
   PubMed Web of Science ®Google Scholar
• Harada Y, Rao VK, Arya K, et al. Combination molecular therapies for type 1 spinal muscular atrophy. Muscle Nerve. 2020;62(4):550–554. DOI:10.1002/mus.27034
   PubMed Web of Science ®Google Scholar
• Lee BH, Collins E, Lewis L, et al. Combination therapy with nusinersen and AVXS-101 in SMA type 1. Neurology. 2019;93(14):640. DOI:10.1212/WNL.0000000000008207
   PubMed Web of Science ®Google Scholar
• Mirea A, Shelby ES, Axente M, et al. Combination therapy with nusinersen and onasemnogene abeparvovec-xioi in spinal muscular atrophy type I. J Clin Med. 2021;10(23):5540. DOI:10.3390/jcm10235540
   PubMed Web of Science ®Google Scholar
• Ferrante L, Melendez-Zaidi A, Lindsey W, et al. Novel use of nusinersen as a therapeutic bridge to onasemnogene abeparvovec-xioi in a premature neonate with type 1 spinal muscular atrophy. Muscle Nerve. 2022;66(2):E8–e10.
   PubMed Web of Science ®Google Scholar
• Osmanovic A, Schreiber-Katz O, Petri S. Nusinersen wearing-off in adult 5q-spinal muscular atrophy patients. Brain Sci. 2021;11(3):367.
   PubMed Web of Science ®Google Scholar
• Zhou H, Meng J, Malerba A, et al. Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy. J Cachexia Sarcopenia Muscle. 2020;11(3):768–782. DOI:10.1002/jcsm.12542
   PubMed Web of Science ®Google Scholar
• Finkel RS, Benatar M. Pre-symptomatic spinal muscular atrophy: a proposed nosology. Brain. 2022;145(7):2247–2249.
   PubMed Web of Science ®Google Scholar
• Farrar MA, Kiernan MC, Kariyawasam DS. Presymptomatic spinal muscular atrophy: a cautionary approach to the proposed new terminology. Brain. 2023. DOI:10.1093/brain/awad061
   PubMed Web of Science ®Google Scholar
• Kariyawasam DS, D’Silva AM, Sampaio H, et al. Newborn screening for spinal muscular atrophy in Australia: a non-randomised cohort study. The Lancet Child Adol Health. 2023;7(3):159–170. DOI:10.1016/S2352-4642(22)00342-X
   Web of Science ®Google Scholar
• Schorling DC, Pechmann A, Kirschner J. Advances in treatment of spinal muscular atrophy – new phenotypes, new challenges, new implications for care. J Neuromuscul Dis. 2020;7(1):1–13.
   PubMedGoogle Scholar
• Tizzano EF. Treating neonatal spinal muscular atrophy: a 21st century success story? Early Hum Dev. 2019;138:104851.
   PubMed Web of Science ®Google Scholar
• Tizzano EF, Finkel RS. Spinal muscular atrophy: a changing phenotype beyond the clinical trials. Neuromuscular Disorders. 2017;27(10):883–889.
   PubMed Web of Science ®Google Scholar
• D’Silva AM, Kariyawasam DS, Best S, et al. Integrating newborn screening for spinal muscular atrophy into health care systems: an Australian pilot programme. Dev Med Child Neurol. 2021;64(5):625–632. DOI:10.1111/dmcn.15117
   PubMed Web of Science ®Google Scholar
• Vill K, Schwartz O, Blaschek A, et al. Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years. Orphanet J Rare Dis. 2021;16(1):153. DOI:10.1186/s13023-021-01783-8
   PubMed Web of Science ®Google Scholar
• Abiusi E, Vaisfeld A, Fiori S, et al. Experience of a 2-year spinal muscular atrophy NBS pilot study in Italy: towards specific guidelines and standard operating procedures for the molecular diagnosis. J Med Genet. 2022;jmg-2022–108873.
   Web of Science ®Google Scholar
• Sumner CJ, Crawford TO. Two breakthrough gene-targeted treatments for spinal muscular atrophy: challenges remain. J Clin Invest. 2018;128(8):3219–3227.
   PubMed Web of Science ®Google Scholar
• Kong L, Valdivia DO, Simon CM, et al. Impaired prenatal motor axon development necessitates early therapeutic intervention in severe SMA. Sci, trans med. 2021;13(578):eabb6871. DOI:10.1126/scitranslmed.abb6871
   PubMed Web of Science ®Google Scholar
• Kariyawasam DST, D’Silva AM, Herbert K, et al. Axonal excitability changes in children with spinal muscular atrophy treated with nusinersen. Journal Of Physiology. 2022;600(1):95–109. DOI:10.1113/JP282249
   PubMed Web of Science ®Google Scholar
• Landfeldt E, Abner S, Pechmann A, et al. Caregiver burden of spinal muscular atrophy: a systematic review. Appl Health Econ Health Pol. 2022;19(4):1–19. DOI:10.1007/s40258-020-00624-2
   Web of Science ®Google Scholar
• Al Amrani F, Amin R, Chiang J, et al. Scoliosis in spinal muscular atrophy type 1 in the nusinersen era. Neurol Clin Pract. 2022;12(4):279–287. DOI:10.1212/CPJ.0000000000001179
   PubMedGoogle Scholar
• Lavie M, Rochman M, Sagi L, et al. Nonrespiratory complications of nusinersen-treated spinal muscular atrophy type 1 patients. Pediatr Pulmonol. 2022;57(3):686–694. DOI:10.1002/ppul.25795
   PubMed Web of Science ®Google Scholar
• Mercuri E, Finkel RS, Muntoni F, et al. Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscular Disorders. 2018;28(2):103–115. DOI:10.1016/j.nmd.2017.11.005
   PubMed Web of Science ®Google Scholar
• Fitzgerald DA, Doumit M, Abel F. Changing respiratory expectations with the new disease trajectory of nusinersen treated spinal muscular atrophy [SMA] type 1. Paediatr Respir Rev. 2018;28:11–17.
   PubMed Web of Science ®Google Scholar
• Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol. 2012;11(5):443–452.
   PubMed Web of Science ®Google Scholar
• Schorling DC, Pechmann A, Kirschner J. Advances in treatment of spinal muscular atrophy - new phenotypes, new challenges, new implications for care. J Neuromuscul Dis. 2020;7(1):1–13.
   PubMedGoogle Scholar
• Montes J, McDermott MP, Martens WB, et al. Six-Minute Walk Test demonstrates motor fatigue in spinal muscular atrophy. Neurology. 2010;74(10):833–838. DOI:10.1212/WNL.0b013e3181d3e308
   PubMed Web of Science ®Google Scholar
• Wadman RI, Vrancken AF, van den Berg LH, et al. Dysfunction of the neuromuscular junction in spinal muscular atrophy types 2 and 3. Neurology. 2012;79(20):2050–2055.
   PubMed Web of Science ®Google Scholar
• Dunaway Young S, Montes J, Kramer SS, et al. Perceived fatigue in spinal muscular atrophy: a pilot study. J Neuromuscul Dis. 2019;6(1):109–117.
   PubMedGoogle Scholar
• Wan HWY, Carey KA, D’Silva A, et al. Health, wellbeing and lived experiences of adults with SMA: a scoping systematic review. Orphanet J Rare Dis. 2020;15(1):70. DOI:10.1186/s13023-020-1339-3
   PubMed Web of Science ®Google Scholar
• Wan HWY, Carey KA, D’Silva A, et al. “Getting ready for the adult world”: how adults with spinal muscular atrophy perceive and experience healthcare, transition and well-being. Orphanet J Rare Dis. 2019;14(1):74.
   PubMedGoogle Scholar
• Yeo CJJ, Darras BT. Overturning the paradigm of spinal muscular atrophy as just a motor neuron disease. Pediatr Neurol. 2020;109:12–19.
   PubMed Web of Science ®Google Scholar
• Palladino A, Passamano L, Taglia A, et al. Cardiac involvement in patients with spinal muscular atrophies. Acta Myol. 2011;30(3):175–178.
   PubMedGoogle Scholar
• Lipnick SL, Agniel DM, Aggarwal R, et al. Systemic nature of spinal muscular atrophy revealed by studying insurance claims. PLoS ONE. 2019;14(3):e0213680. DOI:10.1371/journal.pone.0213680
   PubMed Web of Science ®Google Scholar
• Mendonça RH, Polido GJ, Matsui C, et al. Real-world data from nusinersen treatment for patients with later-onset spinal muscular atrophy: a single center experience. J Neuromuscul Dis. 2021;8(1):101–108. DOI:10.3233/JND-200551
   PubMedGoogle Scholar
• Berti B, Onesimo R, Leone D, et al. Hypoglycaemia in patients with type 1 SMA: an underdiagnosed problem? Arch Dis Child. 2020;105(7):707. DOI:10.1136/archdischild-2019-318120
   PubMed Web of Science ®Google Scholar
• Beattie CE, Kolb SJ. Spinal muscular atrophy: selective motor neuron loss and global defect in the assembly of ribonucleoproteins. Brain Res. 2018;1693(Pt A):92–97.
   PubMedGoogle Scholar
• Kariyawasam D, D’Silva A, Howells J, et al. Motor unit changes in children with symptomatic spinal muscular atrophy treated with nusinersen. J Neurol Neurosurg Psychiatry. 2020;92(1):78–85. DOI:10.1136/jnnp-2020-324254
   PubMed Web of Science ®Google Scholar
• Baptiste C, De Vivo DC. Spinal muscular atrophy: a potential target for in utero therapy. Clin Obstet Gynecol. 2021;64(4):917–925.
   PubMed Web of Science ®Google Scholar
• Prior TW, Krainer AR, Hua Y, et al. A positive modifier of spinal muscular atrophy in the SMN2 gene. Am J Hum Genet. 2009;85(3):408–413. DOI:10.1016/j.ajhg.2009.08.002
   PubMed Web of Science ®Google Scholar
• Calucho M, Bernal S, Alías L, et al. Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscular Disorders. 2018;28(3):208–215. DOI:10.1016/j.nmd.2018.01.003
   PubMed Web of Science ®Google Scholar
• Glascock J, Sampson J, Haidet-Phillips A, et al. Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening. J Neuromuscul Dis. 2018;5(2):145–158. DOI:10.3233/JND-180304
   PubMedGoogle Scholar
• Zhang YH, Zhang YQ, Zhu BS, et al. Association of copy number of SMN1 and SMN2 with clinical phenotypes in children with spinal muscular atrophy. Zhongguo Dang Dai Er Ke Za Zhi. 2019;21(3):239–243.
   PubMedGoogle Scholar
• Swoboda KJ, Prior TW, Scott CB, et al. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol. 2005;57(5):704–712. DOI:10.1002/ana.20473
   PubMed Web of Science ®Google Scholar
• Lee Y, Lee BH, Yip W, et al. Neurofilament proteins as prognostic biomarkers in neurological disorders. CPD. 2020;25(43):4560–4569.
   Google Scholar
• Darras BT, Crawford TO, Finkel RS, et al. Neurofilament as a potential biomarker for spinal muscular atrophy. Ann Clin Transl Neurol. 2019;6(5):932–944. DOI:10.1002/acn3.779
   PubMed Web of Science ®Google Scholar
• Darras, B. T., Crawford, T. O., Finkel, R. S., Mercuri, E., De Vivo, D. C., Oskoui, M., . . . Sumner, C. J. (2019). editors. Neurofilament as a potential biomarker for spinal muscular atrophy. Ann Clin Transl Neurol, 6(5), 932–944. doi:10.1002/acn3.779
   Google Scholar
• Farrar MA, Muntoni F, Sumner CJ, et al. Plasma Phosphorylated Neurofilament Heavy Chain (pNF-H) Level is Associated with Future Motor Function in Nusinersen-treated Individuals with later-onset Spinal Muscular Atrophy (SMA) (2248). Neurology Apr; 2021, 96(15 Supplement) 2248 Neurology Apr 2021, 96 (15 Supplement) 2248
   Google Scholar
• Johannsen J, Weiss D, Daubmann A, et al. Evaluation of putative CSF biomarkers in paediatric spinal muscular atrophy (SMA) patients before and during treatment with nusinersen. J Cell Mol Med. 2021;25(17):8419–8431.
   PubMed Web of Science ®Google Scholar
• Rich KA, Fox A, Yalvac M, et al. Neurofilament Levels in CSF and Serum in an Adult SMA cohort treated with nusinersen. J Neuromuscul Dis. 2022;9(1):111–119. DOI:10.3233/JND-210735
   PubMedGoogle Scholar
• Fetal therapy for spinal muscular atrophy: a case report. Finkel R, Hughers S, Parker J, et al. Late braking abstract presented at World Muscle Society Congress 2022, Halifax, Canada, Oct 2022. WMS Full program, page 32 https://archive.worldmusclesociety.org/www.wms2022.com/file/ff5d5295-702a-40ef-b575-f167017fea05/WMS2022%20Congress%20Programme%20Full%20(25).pdf
   Google Scholar
• Alves CRR, Petrillo M, Spellman R, et al. Implications of circulating neurofilaments for spinal muscular atrophy treatment early in life: a case series. Mol Ther - Methods Clin Dev. 2021;23:524–538.
   PubMed Web of Science ®Google Scholar
• D’Silva AM, Kariyawasam D, Venkat P, et al. Identification of Novel CSF-Derived miRnas in treated paediatric onset spinal muscular atrophy: an exploratory study. Pharmaceutics. 2023;15(1):170.
   PubMed Web of Science ®Google Scholar
• Singh RN, Howell MD, Ottesen EW, et al. Diverse role of survival motor neuron protein. Biochim Biophys Acta, Gene Regul Mech. 2017;1860(3):299–315.
   PubMed Web of Science ®Google Scholar
• Pino MG, Rich KA, Kolb SJ. Update on biomarkers in spinal muscular atrophy. Biomark Insights. 2021;16:11772719211035643.
   Web of Science ®Google Scholar
• Strathmann EA, Peters M, Hosseinibarkooie S, et al. Evaluation of potential effects of Plastin 3 overexpression and low-dose SMN-antisense oligonucleotides on putative biomarkers in spinal muscular atrophy mice. PLoS ONE. 2018;13(9):e0203398. DOI:10.1371/journal.pone.0203398
   PubMed Web of Science ®Google Scholar
• Mercuri E, Baranello G, Kirschner J, et al. Update from SUNFISH Part 1: Safety, Tolerability and PK/PD from the Dose-Finding Study, Including Exploratory Efficacy Data in Patients with Type 2 or 3 Spinal Muscular Atrophy (SMA) Treated with Risdiplam (RG7916) (S25.007). Neurology. 2019: 92(15 Supplement):S25.007
   Google Scholar
• Poirier A, Weetall M, Heinig K, et al. Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs. Pharmacology Research & Perspectives. 2018;6(6):e00447. DOI:10.1002/prp2.447
   PubMed Web of Science ®Google Scholar
• Kariyawasam DST, D’Silva A, Lin C, et al. Biomarkers and the development of a personalized medicine approach in spinal muscular atrophy. Front Neurol. 2019;10:898.
   PubMed Web of Science ®Google Scholar
• Farrar MA, Carey KA, Paguinto SG, et al. Financial, opportunity and psychosocial costs of spinal muscular atrophy: an exploratory qualitative analysis of Australian carer perspectives. BMJ Open. 2018;8(5):e020907.
   PubMed Web of Science ®Google Scholar
• Farrar MA, Carey KA, Paguinto SG, et al. “The whole game is changing and you’ve got hope”: australian perspectives on treatment decision making in spinal muscular atrophy. Patient. 2020;13(4):389–400.
   PubMedGoogle Scholar
• Carey KA, Farrar MA, Kasparian NA, et al. Family, healthcare professional, and societal preferences for the treatment of infantile spinal muscular atrophy: a discrete choice experiment. Dev Med Child Neurol. 2022;64(6):753–761.
   PubMed Web of Science ®Google Scholar
• Ambrosini A, Calabrese D, Avato FM, et al. The Italian neuromuscular registry: a coordinated platform where patient organizations and clinicians collaborate for data collection and multiple usage. Orphanet J Rare Dis. 2018;13(1):176. DOI:10.1186/s13023-018-0918-z
   PubMedGoogle Scholar
• Mercuri E, Messina S, Montes J, et al. Patient and parent oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in SMA. Rome, 13 July 2019. Neuromuscul Disord. 2020;30(5):431–436.
   PubMed Web of Science ®Google Scholar
• Querin G, Lenglet T, Debs R, et al. Development of new outcome measures for adult SMA type III and IV: a multimodal longitudinal study. J Neurol. 2021;268(5):1792–1802. DOI:10.1007/s00415-020-10332-5
   PubMed Web of Science ®Google Scholar
• Butterfield RJ. Spinal muscular atrophy treatments, newborn screening, and the creation of a neurogenetics urgency. Semin Pediatr Neurol. 2021;38:100899.
   PubMed Web of Science ®Google Scholar
• Tabebordbar M, Lagerborg KA, Stanton A, et al. Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species. Cell. 2021;184(19):4919–38.e22. DOI:10.1016/j.cell.2021.08.028
   PubMed Web of Science ®Google Scholar
• MacCannell D, Berger Z, East L, et al. Population pharmacokinetics-based recommendations for a single delayed or missed dose of nusinersen. Neuromuscular Disorders. 2021;31(4):310–318. DOI:10.1016/j.nmd.2021.02.014
   PubMed Web of Science ®Google Scholar
• MacCannell D, Berger Z, Kirschner J, et al. Restoration of nusinersen levels following treatment interruption in people with spinal muscular atrophy: simulations based on a population pharmacokinetic model. CNS Drugs. 2022;36(2):181–190. DOI:10.1007/s40263-022-00899-0
   PubMed Web of Science ®Google Scholar